Caffeine Consumption in Glaucoma Patients and Healthy Subjects
Recruiting · NCT03675412 · Interventional (participants receive a specific treatment) · Lead sponsor: Wills Eye
View the official record on ClinicalTrials.gov →Interventions studied
Caffeine tablet
What this trial is about
Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
Who can take part
Age range
18 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- age 18 to 90 years
- diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)
- healthy subjects with no eye disease
Exclusion criteria
- Diseases, ophthalmic or systemic, that are likely to affect OCTA results
- greater than moderate cataract
- nystagmus
- inability to look at target
- macular degeneration other than mild drusen or pigmentary changes
- diabetic retinopathy
- neovascular glaucoma or non-glaucoma optic neuropathies
- current macular edema, prior laser to retina, inflammatory retinopathy or choroidopathy
- keratoconus, corneal ectasia, central corneal scarring
- rheumatologic diseases or Raynaud's phenomena
- pregnant and lactating women
- mental illness or alcohol addiction
- pre-existing bladder symptoms, cardiac disease or sleep disorder
- refractive spherical diopter greater than 5 or cylinder greater than 3
- possible tolerance to caffeine (drinking more than 1 cup coffee per day).
Where it is running
1 location listed across 1 US state.
- Wills Eye Glaucoma Service - Philadelphia, Pennsylvania, United States